Cookies on this website
We use cookies to ensure that we give you the best experience on our website. If you click 'Continue' we'll assume that you are happy to receive all cookies and you won't see this message again. Click 'Find out more' for information on how to change your cookie settings.

Tebentafusp is being developed as a first-of-its-kind immunotherapy drug that showed promise in clinical studies in helping the immune system fight off melanoma cancers of both the eye and skin.

medical technology and dna concept © CRUK Oxford

 Immunotherapy is a mainstay of cancer treatment, helping the body use its own immune response to attack tumours. Thus far immunotherapy drugs have been used successfully in only some cancer types, such as cutaneous melanoma and lung cancer. These drugs (including checkpoint inhibitors) are less effective in patients whose tumour has fewer immune cells (particularly T cells) and lower mutational burden. This is thought to make it harder for the immune system to ‘see’ and target the tumour.

Metastatic uveal melanoma is one such type of cancer for which this is thought to be a problem, making it one of the deadliest cancers. However, a publication based on a collaboration between the University of Oxford and Immunocore has found that an investigational agent, tebentafusp, designed as a first-in-class bispecific fusion protein, shows the potential to treat both metastatic cutaneous melanoma (mCM, a skin cancer) and metastatic uveal melanoma (mUM, an eye cancer).

The full article is available to read on the Cancer Research UK - Oxford Centre website

Similar stories

New form of gift wrap drives male reproductive success

General Research

A study from the Department of Physiology, Anatomy and Genetics (DPAG) has identified a new communication mechanism that ensures the transfer of a complex mix of signals and nutrients required for successful reproduction between males and females.

PRINCIPLE trial finds antibiotics azithromycin and doxycycline not generally effective treatments for COVID-19

Coronavirus COVID-19 General Research

In March 2020, the UK-wide Platform Randomised trial of INterventions against COVID-19 In older people (PRINCIPLE) trial was established as a flexible, platform randomised clinical trial to test a range of potential treatments for COVID-19 that might be suitable for use in the community to help people recover more quickly and prevent the need for hospital admission. The trial is one of three national platform trials for COVID-19 treatments, and complements the RECOVERY and REMAP-CAP trials that focus on hospitalised patients.

Early animal studies yield promising results for new potential COVID-19 vaccine

Coronavirus COVID-19 General Research

Studies carried out in the MRC Human Immunology Unit (MRC HIU) in collaboration with the Pirbright Institute have shown that a new potential vaccine against COVID-19, named RBD-SpyVLP, produces a strong antibody response in mice and pigs, providing vital information for the further development of the vaccine. Although this type of vaccine is not a competitor for the first wave of vaccines, it is hoped that it will be useful as a standalone vaccine or as a booster for individuals primed with a different COVID-19 vaccine.

Just over half of British Indians would take COVID vaccine

Coronavirus COVID-19 General Research

University of Oxford researchers from the Department of Physiology, Anatomy and Genetics (DPAG) and the Department of Psychiatry, in collaboration with The 1928 Institute, have published a major new study on the impact of COVID-19 on the UK’s largest BME population.

Investigating New Treatment for Schizophrenia

General Innovation Research

A partnership between University of Oxford, the Earlham Institute, and the global pharmaceutical companies Biogen Inc and Boehringer Ingelheim is announced today to investigate a new drug target for the treatment of schizophrenia.